IP Library Granted Patent US 9,321,840
Granted Patent B2
US 9,321,840 · App. 14/309,118 · Granted Apr 26, 2016

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,321,840
App. No.
14/309,118
Granted
Apr 26, 2016
Kind
B2
Abstract

This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Claims (22)

1. An isolated nucleic acid molecule encoding a chimeric or humanized CD154 binding antibody comprising heavy chain CDR1, CDR2 and CDR3 sequences selected from:

(a) SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively;

and comprising light chain CDR1, CDR2 and CDR3 sequences selected from:

(a) SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

2. The isolated nucleic acid molecule according to claim 1 , wherein said nucleic acid molecule is a DNA molecule comprising a sequence selected from SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 41, SEQ ID NO: 70 or SEQ ID NO: 73 or comprising a sequence selected from a sequence at least 90% identical to SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 41, SEQ ID NO: 70 or SEQ ID NO: 73.

3. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes an chimeric or humanized CD154 binding antibody that is engineered to have reduced effector functions.

4. An isolated vector comprising a nucleic acid molecule of claim 1 .

5. An isolated host cell comprising a vector of claim 4 .

6. The isolated host cell according to claim 5 , wherein the host cell is a prokaryotic cell.

7. The isolated host cell according to claim 5 , wherein the host cell is a eukaryotic cell.

8. A method for producing a chimeric or humanized CD154 binding antibody comprising the steps of:

(a) culturing a host cell of claim 5 under conditions suitable for expression of the chimeric or humanized antibody by the host cell; and

(b) recovering the chimeric or humanized antibody.

9. The method according to claim 8 , wherein the host cell is a prokaryotic or a eukaryotic cell.

10. An isolated vector comprising a DNA molecule of claim 2 .

11. An isolated host cell comprising a vector of claim 10 .

12. The isolated host cell according to claim 11 , wherein the host cell is a prokaryotic cell.

13. The isolated host cell according to claim 11 , wherein the host cell is a eukaryotic cell.

14. A method for producing a chimeric or humanized CD 154 binding antibody comprising the steps of:

(a) culturing a host cell of claim 11 under conditions suitable for expression of the chimeric or humanized antibody by the host cell; and

(b) recovering the chimeric or humanized antibody.

15. The method according to claim 14 , wherein the host cell is a prokaryotic or a eukaryotic cell.

Assignments (6)
CHANGE OF NAME Recorded Feb 13, 2021
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 055301/0440 →
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNOR PREVIOUSLY RECORDED ON REEL 033187 FRAME 0108. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Jul 14, 2014
From: UCB PHARMA S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 033312/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2014
From: UCB BIOPHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 033187/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2014
From: ADAMS, RALPH; BROWN, DEREK THOMAS; POPPLEWELL, ANDREW GEORGE; ROBINSON, MARTYN KIM; SHOCK, ANTHONY; TYSON, KERRY LOUISE
To: UCB PHARMA S.A.
Reel/Frame 033159/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2014
From: BURKLY, LINDA C.; FERRANT-ORGETTAS, JANINE L.; GARBER, ELLEN A.; HSU, YEN-MING; SU, LIHE; TAYLOR, FREDERICK R.
To: BIOGEN IDEC MA INC.
Reel/Frame 033159/0025 →